
Xylyx Bio Xylyx is developing first-in-class bioengineered human whole organ grafts to significantly increase the number of organs available for life-saving transplantation, increase hospital transplant volume, and reduce payor costs associated with end-stage disease. The company’s lead program in lung completed IND-enabling studies, has been granted FDA orphan designation, and is poised for historic first-in-human transplants, with parallel pipeline development in liver, kidney, and heart. Therapeutic Developer

Xylyx Bio

Xylyx is developing first-in-class bioengineered human whole organ grafts to significantly increase the number of organs available for life-saving transplantation, increase hospital transplant volume, and reduce payor costs associated with end-stage disease. The company’s lead program in lung completed IND-enabling studies, has been granted FDA orphan designation, and is poised for historic first-in-human transplants, with parallel pipeline development in liver, kidney, and heart.

Therapeutic Developer